Voloridge Investment Management’s Amneal Pharmaceuticals AMRX Stock Holding History

Voloridge Investment Management’s Portfolio AMRX Stock Details AMRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-204,883	Closed	-$2.55M	–	800
2026 Q1	$2.55M	Sell	204,883 -358,797	-64%	-$4.82M	0.01%	793
2025 Q4	$7.1M	Buy	563,680 +328,253	+139%	+$3.76M	0.03%	670
2025 Q3	$2.36M	Buy	+235,427	New	+$2.11M	0.01%	906
2025 Q2	–	Sell	-35,574	Closed	-$298K	–	1149
2025 Q1	$298K	Buy	+35,574	New	+$297K	﹤0.01%	1122
2024 Q1	–	Sell	-50,503	Closed	-$307K	–	1137
2023 Q4	$307K	Buy	+50,503	New	+$225K	﹤0.01%	1079
2021 Q2	–	Sell	-57,822	Closed	-$389K	–	1593
2021 Q1	$389K	Buy	+57,822	New	+$320K	﹤0.01%	1222
2020 Q2	–	Sell	-51,034	Closed	-$178K	–	1238
2020 Q1	$178K	Buy	+51,034	New	+$216K	0.01%	973
2019 Q4	–	Sell	-85,825	Closed	-$249K	–	1067
2019 Q3	$249K	Buy	85,825 +2,453	+3%	+$8.56K	﹤0.01%	968
2019 Q2	$598K	Buy	+83,372	New	+$852K	0.02%	537

Other funds holding AMRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Voloridge Investment Management's AMRX Position: Q2 2026 in Review

Voloridge Investment Management sold out of Amneal Pharmaceuticals (AMRX) in Q2 2026, closing a stake of 204,883 shares — an estimated $2.55M sold.

Voloridge Investment Management first reported a position in AMRX in Q2 2019 and held it in 9 quarters. The position peaked at $7.1M in Q4 2025. 311 funds tracked by Wall St. Rank hold AMRX as of Q2 2026.

Voloridge Investment Management reported no remaining Amneal Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Voloridge Investment Management sold 204,883 Amneal Pharmaceuticals shares in Q2 2026, an estimated $2.55M.
Voloridge Investment Management first reported a position in Amneal Pharmaceuticals in Q2 2019 and held it in 9 quarters.
Voloridge Investment Management's Amneal Pharmaceuticals position peaked at $7.1M in Q4 2025.
311 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q2 2026.

Based on Voloridge Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.